Actively Recruiting
Randomized, Double-blind Study to Assess the Safety and Effectiveness of CnU Capsule 500 mg in Adults With Biliary Dyspepsia
Led by Myungmoon Pharma. Co. Ltd. · Updated on 2026-07-29
358
Participants Needed
8
Research Sites
30 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of CnU capsule 500 mg in adults with biliary dyspepsia, a condition causing pain in the upper abdomen related to gallbladder and bile duct function. This Phase 4 clinical trial is designed as a multi-center, randomized, double-blind, placebo-controlled study to carefully assess symptom improvement and overall safety. Participants are randomly assigned to receive either the CnU capsule 500 mg or a placebo capsule, taken orally once daily after meals for 24 weeks. The study uses a parallel design, with treatments given at about the same time each day. Both groups are monitored throughout the treatment period for changes in symptoms and quality of life. During the 24-week study, participants will be evaluated using the Global Overall Symptom Scale GOS at the start and at Week 24 to measure symptom improvement. Additional assessments include symptom scores and quality of life measures at baseline, Week 4, Week 12, and Week 24. The study team will monitor participant safety and treatment adherence throughout, with the goal of understanding the impact of CnU capsule on biliary dyspepsia symptoms.
CONDITIONS
Brief Title
A Study to Evaluate the Efficacy and Safety of CnU Cap. 500 mg in Patients With Biliary Dyspepsia
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here